Background: Assays for endogenous ouabain, a cardiac glycoside believed to be involved in blood pressure and volume regulation, are characterized by laboratory-specific plasma values that are measured by different assays. Because of this variability, our study focused on the development of a new 125 I-labeled ouabain derivative for RIA of high sensitivity. Methods: We generated rabbit antisera against a ouabain-thyroglobulin conjugate. A tyrosylated ouabain derivative for radioiodination was synthesized using periodate and sodium cyanoborohydride reagents. Results: Mass spectrometric analyses showed that the main product of the tyrosylating reaction was tyrosylouabain (molecular mass, 702 Da). This was radioiodinated with Chloramine-T and used as a tracer in a RIA, which gave an assay detection limit of 5 pmol/L (4 ng/L), 2-100 times lower than that in the corresponding 3 H-RIAs and 2-20 times lower than ouabain ELISAs, making it possible to measure low plasma concentrations of immunoreactive ouabain. Different amounts of SepPak C 18 -extracted plasma samples displaced the 125 I-labeled tyrosyl-ouabain tracer at the same rate at which authentic ouabain was displaced. Plasma immunoreactive ouabain coeluted with authentic ouabain in two different HPLC conditions. Using the new RIA, we found plasma ouabain concentrations, assayed as immunoreactive equivalents, of 10.0 ؎ 1.3 pmol/L in healthy women and 12.0 ؎ 0.9 pmol/L in healthy men (mean ؎ SE; n ‫؍‬ 10), as well as 41.2 ؎ 9.6 pmol/L in rats. The concentrations were 2-90 times lower than those previously reported using different assay methods.
A sodium-potassium pump inhibitor has been isolated and chemically characterized from human plasma (1, 2 ) , bovine hypothalamus (3) (4) (5) , and bovine adrenals (6, 7 ) . Several studies, especially one using nanogram-scale chemical derivatization (4 ) , have indicated that the compound isolated from human plasma and bovine hypothalamus is an isomer of ouabain, rather than ouabain itself. However, in recent studies using microgram amounts of purified material (5, 7 ) , molecular mass and proton nuclear magnetic resonance ( 1 H NMR) 4 spectroscopic measurements have demonstrated that the adrenal and hypothalamic sodium pump inhibitors are indistinguishable from authentic ouabain. Because cardiac glycosides, such as ouabain, inhibit Na ϩ ,K ϩ -ATPase (8 ) and thus increase intracellular sodium, they might have a physiological role (e.g., during pregnancy) as endogenous natriuretic and vasoactive substances. Increased concentrations of immunoreactive ouabain have been observed in hypertensive patients, indicating that the measurement of an endogenous ouabain-like compound might have clinical interest (9, 10 ) , especially because there are studies showing an endogenous, i.e., adrenocortical, origin of this compound (6, 11 ) .
According to data available, plasma immunoreactive ouabain concentrations are laboratory-specific (12 ) , indicating that reliable measurement is not without problems. Cardiac glycosides conjugated to proteins are good immunogens, and several groups have been able to establish enzyme and 3 H-immunoassays for the measurement of ouabain immunoreactivity in body fluids (13) (14) (15) (16) (17) (18) . RIAs and ELISAs are notoriously prone to nonspecific interfer-ence when used to measure picomolar, i.e., low endogenous concentrations of biologically active substances. This may be a reason for the different plasma ouabain equivalents reported previously, varying from Ͻ5 pmol/L (15 ) to 100 -300 pmol/L (14, 17, 18 ) to Ն1000 pmol/L (13 ) for human plasma, and from Յ50 pmol/L (19 ) to Ն200 pmol/L for rat plasma (18 ) in solid-phase-extracted samples. It has even been reported that the immunoreactive ouabain in human plasma is not authentic ouabain because in some HPLC analyses of plasma extracts, no immunoreactivity was observed at the elution position of authentic ouabain (15, 20 ) . These discrepant results indicate the need for further development of ouabain assay methods suitable for physiological and clinical studies.
In the present study, we raised in rabbits high-affinity polyclonal antisera against ouabain and synthesized a new 125 I-labeled tyrosyl-ouabain derivative for use as a tracer of high specific activity. The new RIA could be used, in conjunction with solid-phase extraction, for routine measurement of an endogenous ouabain-like compound present in biological samples.
Materials and Methods materials
Ouabain (G-strophanthin) octahydrate, ouabagenin, dihydroouabain, digoxin, digitoxin, digoxigenin, and other related steroids (aldosterone, bufalin, cortisone, hydrocortisone, progesterone, ␤-estradiol, estrone, testosterone, and dehydroepiandrosterone), bovine thyroglobulin, and sodium cyanoborohydride were obtained from Sigma. Freund's incomplete and complete adjuvants were purchased from Difco Laboratories, l-tyrosine and polyethylene glycol 6000 were from Fluka AG, [ 3 H]ouabain ( [21, H]ouabain) and Na 125 I (IMS 300) were from Amersham Pharmacia Biotech, and Sephadex G-50F was from Pharmacia Fine Chemicals. NaIO 4 , Chloramine-T, and all other chemicals were obtained from E. Merck AG.
preparation of ouabain antigen and antisera
Ouabain was coupled with bovine thyroglobulin as described by Masugi et al. (13 ) . Ouabain (29 mg) was allowed to react with NaIO 4 (11 mg) in distilled water overnight at 4°C. Ethanol (1 mL) was then added, and the reaction solution was adjusted to pH 8 with 1 mol/L NaOH. Finally, bovine thyroglobulin (20 mg dissolved in 1 mL of 0.05 mol/L sodium phosphate, pH 9) was added dropwise to 1 mL of the reaction solution (14.5 mg of ouabain and 5.5 mg of NaIO 4 ). After vortex-mixing and incubation for 2 h, sodium cyanoborohydride (2.5 mg in 200 L of distilled water) was added and the reaction solution was applied to a gel filtration column (Sephadex G-50F in 9 g/L NaCl) for fractionation. The ouabainthyroglobulin conjugate, eluting in the void volume, was emulsified in Freund's complete adjuvant and injected into five rabbits (1 mg of conjugate per rabbit). Booster injections of 0.5 mg per rabbit, emulsified in Freund's incomplete adjuvant, were given at monthly intervals. As measured by the absorbance at 219 nm, the hapten-carrier ratio of the conjugate was 160:1.
preparation of radioiodinated ouabain tracer
Ouabain was first coupled with l-tyrosine with a method analogous to the one described above. After the reaction of ouabain (3.1 mg) with NaIO 4 (1.4 mg) in distilled water (0.1 mL), ethanol was added to the reaction solution, and the pH was adjusted to 8. l-Tyrosine (0.8 mg in 0.4 mL of 0.05 mol/L sodium phosphate, pH 9) was then added dropwise, followed by incubation for 2 h. Sodium cyanoborohydride (0.25 mg in 0.2 mL of distilled water) was added, and the reaction solution was fractionated by reversed-phase HPLC [Vydac C 18 column; 30-min linear 5-50% methanol gradient in 0.5 mL/L trifluoroacetic acid (TFA); flow-rate, 1.0 mL/min]. The main peak with ultraviolet (UV) absorbance in the HPLC profile of the tyrosylating solution (23 min) was used for radioiodination as follows: Tyrosyl-ouabain (1 g) was allowed to react with Na 125 I (19 MBq) in the presence of Chloramine-T (10 g); after 30 s, sodium metabisulfite (10 g) was added, and the reaction solution was applied into the HPLC column (Vydac C 18 ) for reversed-phase fractionation (30-min 10 -40% acetonitrile gradient in 1 mL/L TFA; flow-rate, 1.0 mL/min).
mass spectrometric analyses of tyrosyl-ouabain
The main peak (23 min), as detected by UV absorbance, in the HPLC separation of the tyrosylating reaction products of ouabain was further purified in another HPLC using a Waters SymmetryShield TM RP 8 column and a 30-min gradient from 0% to 30% methanol in distilled water with a flow rate of 1.0 mL/min. The product (0.2-10 g) was analyzed with a quadrupole time-of-flight tandem instrument (Micromass Ltd) equipped with electrospray ionization and atmospheric pressure chemical ionization (APCI) sources. The sample was infused at a 1:1000 dilution in acetonitrile-water (50:50 by volume) containing 2 mL/L formic acid into the electrospray source, using a syringe pump (Harward Apparatus).
SepPak solid-phase extraction of plasma samples
Human blood from healthy adults taking no medication was collected from an antecubital vein into EDTA tubes at 9 -10 h. Rat blood was obtained by decapitation of adult Sprague-Dawley rats of both sexes at 9 -10 h. The blood samples were immediately centrifuged, and the plasmas were stored at Ϫ20°C. For ouabain measurements, the plasma samples were extracted using SepPak C 18 cartridges (Waters) and an automated Gilson Aspec system. Briefly, the cartridges were preconditioned with 2-propanol and 1 mL/L TFA. The 1-mL plasma samples were acidified with 0.2 mL of 1 mol/L HCl containing 16 g/L glycine and passed through the cartridges. After a 2-mL wash with 1 mL/L TFA, ouabain was eluted with 3 mL of 400 mL/L acetonitrile in 1 mL/L TFA. After evaporation in a SpeedVac (Savant Instruments), the extracts were reconstituted in 250 L of RIA buffer.
ria procedure
The calibrators and samples were pipetted in duplicates of 100 L. The antiserum (a-ouabain-199-13-4-95) and tracer were added simultaneously (total volume added, 100 L). After an overnight incubation, the bound and free fractions were separated by double-antibody precipitation for 15 min at room temperature. Precipitation was accelerated by the addition to the assay tubes of polyethylene glycol 6000 in a final concentration of 57 g/L. The precipitates were counted in a CliniGamma gamma counter (Wallac). For 3 H measurements, the precipitates were resuspended in 250 L of distilled water, transferred into counting vials containing scintillation fluid, and counted in a Wallac beta counter (16 ) .
ria validation
Serial dilutions of SepPak extracts of human and rat plasma were assayed against the ouabain calibrator. Plasma extracts were also analyzed by reversed-phase HPLC, using a 4.6 ϫ 150 mm Vydac C 18 218 TP column (Separations Group) and a 30-min linear gradient from 5% to 50% acetonitrile in 1 mL/L TFA with a flow rate of 1.0 mL/min. The fractions were dried in a SpeedVac, redissolved in RIA buffer, and subjected to the ouabain RIA. From a selected chromatographic run, one-third of the peak fraction with ouabain immunoreactivity was reanalyzed in another HPLC system with different selectivity, using a 4.6 ϫ 250 mm Vydac C 8 228TP pH-stable column and a 30-min linear gradient from 0% to 30% acetonitrile in 1 mL/L TFA with the flow rate of 1.0 mL/min. Blank runs, using water as the sample, were carried out for both HPLC systems to control for background immunoreactivity.
Results

antiserum titer
All five rabbits produced ouabain antisera against the ouabain-thyroglobulin conjugate. After the first booster, the titers were 1:3000 -1:7000 with the tritiated tracer and 1:300 000 -1:1 000 000 with the radioiodinated tracer. The titer could be maintained or even increased for at least 1 year with monthly boosters ( Table 1 ). The antiserum bleed selected for RIA use (see below) bound 30% of the 125 I-labeled tyrosyl-ouabain tracer (estimated specific activity, 2100 Ci/ mmol) at a final dilution of 1:2 000 000 ( Table 1) . By comparison, a dilution of 1:14 000 of the same antiserum was required to bind 30% of [ 3 H]ouabain tracer (specific activity reported by the manufacturer, 20 Ci/mmol).
radioiodinated ouabain tracer
The coupling of tyrosine to ouabain yielded several products separable by HPLC. As seen in Fig. 1 , the main peak, as detected by UV absorbance, in the first HPLC purification step eluted at 23 min, 5 and 15 min later than ouabain and tyrosine, respectively. Radioiodination of the main peak and subsequent purification by reversed-phase HPLC yielded a radioactive product that showed high binding affinity to the ouabain antisera ( Table 1 ). The 125 I-labeled tyrosyl tracer was relatively stable and could be used in the RIA for 4 months when stored at Յ10°C.
mass spectrum of tyrosyl-ouabain
The APCI mass spectrum of the main HPLC peak of the coupling reaction solution is shown in Fig. 2 . The mass of the suggested protonated molecule was 702 Da. Furthermore, the exact mass measurements done using the electrospray mode showed that the [M-H] ϩ ion of tyrosylouabain was 702.3510 Da, corresponding to the molecular Fig. 1 . HPLC separation of periodate/cyanoborohydride reaction products of ouabain and tyrosine using a Vydac C 18 column and a 30-min linear gradient from 5% to 50% acetonitrile in 0.5 mL/L TFA.
Tyrosine, ouabain, and the main reaction product eluted as peaks at 8, 18, and 23 min, respectively, as measured by UV absorbance at 220 nm (A 220 ). Fig. 3 shows the postulated reaction mechanism of ouabain and tyrosine based on the schedule of Harris et al. (14 ) . The schedule leads to a tyrosylouabain conjugate with a formula mass of 702 Da.
assay characteristics
As seen in Table 1 , the assay detection limit (defined at 5% displacement of tracer) for each antiserum was Յ1.8
fmol/tube (Յ1.3 pg/tube), which corresponded to a plasma concentration of Յ5 pmol/L (Յ3 ng/L). The 50% displacement was achieved at 6 -14 fmol (4 -10 pg). Fig. 4 demonstrates that the assay detection limit is 0.6 fmol/ tube (0.4 pg/tube) with the 125 I-labeled tyrosyl tracer and 44 fmol/tube (32 pg/tube) with the 3 H tracer, using the antiserum a-ouabain-199 selected for RIA use. The displacement was linear between 3 and 50 fmol. The specificities of the different antisera were tested with ouabain, digitalis, and related compounds as well as with several steroids. The cross-reactivity data of a-ouabain-199 are presented in Table 2 . Ouabagenin showed the highest cross-reactivity (52%), followed by digoxin (1.7%) and digitoxin (0.6%), whereas the cross-reactivity of all steroids was Ͻ0.001%. The intraassay CVs for low (6.5 pmol/L), medium (37 pmol/L), and high (168 pmol/L) ouabain concentrations were 8.5%, 3.7%, and 4.3%, respectively (n ϭ 10). The interassay CVs for low (15 pmol/L), medium (42 pmol/L), and high (167 pmol/L) ouabain concentrations were 13%, 9.4% and 10%, respectively (n ϭ 10). Nonspecific binding was 1-2%.
ria validation
Different amounts of plasma solid-phase extracts displaced 125 I-labeled tyrosyl-ouabain tracer in parallel with the authentic ouabain calibrator (Fig. 4 ). Immunoreactive ouabain in human and rat plasma extracts coeluted with authentic ouabain in two different reversed-phase HPLC conditions (at 14 min in the first and 12 min in the second Fig. 2 . APCI mass spectrum of the main coupling product of ouabain and tyrosine purified in two HPLC systems. Fig. 3 . Postulated two-phase reaction mechanism in the coupling of ouabain and tyrosine by periodate (NaIO 4 ) and sodium cyanoborohydride (NaBH 3 CN) reagents.
Carbon, hydrogen, and oxygen losses are indicated in the boxes.
HPLC system; see Fig. 5 ). The recovery of added ouabain in a HPLC test run was 89.6%. No ouabain immunoreactivity was detected in the blank samples.
plasma concentrations of immunoreactive ouabain in healthy humans and rats
The recovery of ouabain added to human plasma samples (1 mL) from solid-phase extraction with SepPak C 18 cartridges was 102.8% Ϯ 2.5% (mean Ϯ SE; n ϭ 5) for a low dose (34 fmol added) and 93.6% Ϯ 1.3% for a high dose (103 fmol added). In accordance with these results, the recovery in acidic extraction conditions with respect to neutral conditions (HCl and TFA replaced with distilled water) was 97.5% Ϯ 2.1% (mean Ϯ SE; n ϭ 6). Plasma samples (1 mL) from healthy adult women and men and from adult rats of both sexes were extracted by the solid-phase cartridges and measured in the ouabain RIA. The plasma concentrations were 10.0 Ϯ 1.3 pmol/L (mean Ϯ SE) in women 22-45 years of age (n ϭ 10), 12.0 Ϯ 0.9 pmol/L in men 23-55 years of age (n ϭ 10), and 41.2 Ϯ 9.6 pmol/L in rats.
Discussion
In the present study, we developed a 125 I-RIA for ouabain measurements with a detection limit almost 100-fold lower than that of our corresponding 3 H-RIA. The key components in our method are the new 125 I-labeled tyrosyl-ouabain tracer and the high-affinity ouabain antiserum. The work was based on our previous results involving the synthesis and use of a radioiodinated tracer in melatonin RIA (21, 22 ) . We adopted a modification of the method of Masugi et al. (13 ) to make the ouabainthyroglobulin conjugate, which was used as an immunogen, and to make the ouabain-tyrosine conjugate, which was used to prepare radioiodinated tracer for the RIA. In both cases, the insertion probably takes place in the sugar moiety of ouabain. This is supported by the cross-reactivity profile of the ouabain antiserum (a-ouabain-199) raised against the ouabain-thyroglobulin conjugate, which demonstrated the highest cross-reactivity (52%) to the aglycone ouabagenin. The steroid nucleus with its hydroxyl groups and apparently also the lactone ring thus form the antigenic determinant. Previously, Takemura et al. (23 ) used periodate to cleave the sugar ring of digoxin. However, they used 2-hydroxy-3-methylbenzoyl-hydrazide, instead of sodium cyanoborohydride, in the preparation of a derivative for radioiodination. This derivatization did not eliminate the biologic or immunologic activity of digoxin. In some digoxin assays, radioiodinated tracers have also been prepared by coupling digoxigenin to tyrosine via succination without periodation (24 ) .
We characterized the structure of the synthesized putative tyrosyl-ouabain by mass spectrometry. The product was first purified to homogeneity by reversed-phase HPLC. APCI analysis gave a molecular ion mass of 702 Da. Interestingly, this is consistent with the reaction mechanism proposed by Harris et al. (14 ) for ouabain and bovine serum albumin. In this proposed two-phase reaction mechanism, the rhamnose moiety of ouabain is first opened by periodation, losing a carbon atom, a water molecule, and two hydrogen atoms. Subsequently, in the coupling phase, the side chain of the tyrosine molecule is attached to the opened rhamnose moiety of ouabain when two more oxygen atoms are lost. The mechanism would provide a molecular mass of exactly 702 Da to the product, tyrosyl-ouabain.
Several studies have shown that human plasma contains a cardiac glycoside, i.e., a ouabain-digitalis-like factor, the structure of which is indistinguishable from plant-derived ouabain as judged from various HPLC, mass spectrometric, and RIA analyses (1, 2, 13, 14, 17, 18, (25) (26) (27) . However, a mass spectrometric analysis by Mathews et al. (27 ) raised the possibility of slight differences in hydroxylation positions of the steroid nucleus of the human plasma compound. Initially, this review was reinforced by studies using nanoscale fluorescent naphthoylate derivatives of the human and bovine compounds (3, 4 ) . However, recent NMR studies (5 ) showed that the bovine compounds formed complexes with borate under isolation conditions and NMR processes carried out in borosilicate glassware (4, 5 ) . Therefore, although not confirmed by direct observation, it was inferred that the bovine hypothalamic compound as isolated would have been indistinguishable from ouabain. Furthermore, another recent study based on mass spectrometric and 1 H NMR analyses showed that the compound isolated from the bovine adrenal glands was also indistinguishable from ouabain (7 ) . Thus, it now seems that the endogenous bovine adrenal and hypothalamic ouabain-like material is ouabain (circulating compound remains to be resolved).
Circulating ouabain or ouabain-like activity has been measured by many techniques, including bioassays, radioreceptor assays using membrane fractions from sev-eral tissues (28 ) , and ouabain and digoxin immunoassays. The bioassay methods, which are based on Na ϩ ,K ϩ -ATPase inhibition (ATP hydrolysis by the sodium pump or the inhibition of the in-trans location activity of the Na ϩ ,K ϩ -ATPase) are ouabain-specific and have been used to verify the authenticity of isolated endogenous compounds. These methods are not ideal for routine measurements because they are cumbersome and have lower sensitivities than immunoassays.
The available ouabain immunoassays have recently been compared in reviews by Semra et al. (16 ) and by us (12 ) . Although the best enzyme immunoassays and RIAs are believed to possess detection limits (10 -30 pmol/L) suitable for physiological studies, widely varying plasma concentrations, ranging from 0.04 to 1.1 nmol/L, have been reported for healthy adults in different studies (13) (14) (15) (16) (17) (18) . Moreover, no circulating ouabain immunoreactivity was detected in some studies (15, 20 ) . These laboratory-specific results might be related to differences in antiserum specificity and sensitivity; the use of different tracers, generally [ 3 H]ouabain and enzyme-linked ouabain analogs; the use of different sample volumes, causing variable matrix effects; and/or the presence of potential interfering factor(s) in plasma, leading to overestimation of concentrations (17, 28 ) . Because of the laboratory-specific differences, a reference interval of normal concentrations cannot be reliably inferred, especially when sufficient validation has not been carried out in all studies regarding the substance measured in the assay. Thus, at present, ouabain equivalents are preferred over ouabain, meaning that from a methodological perspective, plasma measurements are lacking a laboratory routine.
Therefore, it was necessary for us to carry out several validation tests giving special attention to the identity of plasma immunoreactivity measured in our RIA. We found that the extraction of plasma samples is essential for valid measurements. The SepPak C 18 reversed-phase extraction method provided necessary purification and a nearly complete recovery of ouabain added to human plasma and rat samples. Validation of quantification of plasma immunoreactive ouabain was demonstrated by the parallel dilution of plasma extracts with the ouabain calibrator. Furthermore, additional support for the analytical validity of the measurements was obtained by the finding that immunoreactive ouabain in human plasma extracts coeluted with authentic ouabain in two reversedphase HPLC systems with different selectivities. Moreover, our assay detected the previously isolated ouabainlike compound from human plasma (endogenous ouabain discovered by Hamlyn) with high cross-reactivity (12 ) .
The results obtained with our new sensitive RIA support previous findings that ouabain itself or ouabain-like compound is present in normal human plasma (1, 2, 13, 14, 18, 26, 27 ) . In the present study, we were able to detect immunoreactive ouabain both before and, unlike in the study of Lewis et al. (15 ) , after HPLC fractionation. According to our plasma measurements, however, immunoreactive ouabain concentrations are low in healthy adults, 1.5-to 3-fold lower than those reported in the most sensitive enzyme immunoassay-based and 3 H-RIA studies (19, 29, 30 ) .
In conclusion, we have synthesized and characterized by mass spectrometry a tyrosyl-ouabain conjugate suitable for radioiodination. The new molecule made possible development of a ouabain 125 I-RIA with superior sensitivity. Coupled with solid-phase extraction of plasma samples, the assay reliably detects immunoreactive ouabain concentrations of 5 pmol/L. In our HPLC and other validation tests, this immunoreactive ouabain behaved like authentic ouabain. Thus, our RIA allows measurement of the proposed low endogenous ouabain equivalents in both physiological and pathophysiological situations. The new method provides an analytical tool with which it is possible to establish the potential homeostatic and clinical significance of endogenous ouabain.
